ARFA COMBI IN THE TREAT-MENT OF PATIENTS WITH TYPE 2 DIABETES AND DYS-LIPIDEMIA

The increase in the number of obese individuals, chronic stress as well as a sed-entary lifestyle result in continuous progression of type 2 diabetes mellitus (DM). Such patients develop dyslipidemia that plays a key role in increasing cardiovascular risk (CVR) being the leading cause of increased mortality. In addition to the normalization of glycemic parameters, the priority in treatment of patients with DM is the correction of dyslipidemia. The objective of our research was to study whether a dietary supplement Arfa Combi has sufficient hypoglycemic and lipid-lowering effects as well as to analyze whether there is a significant reduction in the levels of total cholesterol and triglycerides in patients with type 2 DM. The article presents the data on the use of dietary supplement Arfa Combi in patients with type 2 DM and dyslipidemia. 60 patients with type 2 DM (50% of males and 50% of females) were examined in the Vinnytsia Regional Highly Specialized Clinical Endocrinology Center. The average patients' age was 39-69 years. Anthropometric measurements indicated that all the patients had grade I obesity (body mass index (BMI) - 30-34.9 kg/m2), moderate or severe type 2 DM without pronounced diabetic complications. Inclusion criteria were moderate or severe type 2 DM with the disorders of lipid metabolism in the form of dyslipidemias and/or hypercholesteremia if statins were not taken over the last 3 months. All the patients were divided into 3 groups of 20 people: patients of Group I received dietary supplement Arfa Combi and statins; patients of Group II received dietary supplement Arfa Combi only; patients of Group III received statins only on the background of hypoglycemic therapy. During treatment, all the patients underwent fasting glucose testing, the 2-hour glucose tolerance test as well as the determination of the levels of total cholesterol and triglycerides. Arfa Combi can be used as an additional dietary supplement in various clinical forms of DM. According to the results of our study, Arfa Combi can be used as monotherapy for carbohydrate metabolism disorders (fasting hyperglycemia or impaired carbohydrate to-lerance). A significant reduction in triglyceride levels in patients with DM was the main ad-vantage of Arfa Combi. Dietary supplement Arfa Combi is an effective and safe preparation for using in combination treatment of patients with type 2 DM for the correction of carbohydrate and lipid disorders. The preparation may be used as monotherapy or in combination with other drugs.